Xspray-logo-white
  • Home
  • About us
    • Business model
    • Our history – a timeline
    • Board of Directors & Board committees
    • Management
  • Technology
  • Pipeline
  • Media
  • Contact
  • Investors
  • en en
    • sv sv
  • Investors
    • Share information
      • Analysts
      • Trading information
      • Ownership structure
    • Financial calendar & Events
    • Financial reports
      • ESEF report
    • Prospectus
    • Press releases
    • Corporate governance
      • Corporate Structure
      • General meetings
      • Corporate Governance Reports
      • Nomination committee
      • Board of Directors & Board committees
      • Management
      • Accounting principles
      • Internal control & Risk management
      • Auditor
      • Articles of association
      • Renumeration

Press releases

All press releases Regulatory

Regulatory press release 2021-02-17

Nomination Committee proposes Anders Ekblom as new Chairman of the Board in Xspray Pharma

Regulatory press release 2021-01-29

Number of shares and votes in Xspray Pharma

Regulatory press release 2021-01-26

Warrant holders exercise all warrants within the framework of the incentive program

Regulatory press release 2021-01-22

Xspray Pharmas study with modified formulation of HyNap-Dasa has now started

Regulatory press release 2021-01-14

Xspray Pharma announces results from additional bioequivalence study and provides update regarding upcoming regulatory applications for ANDA and 505(b)(2)

Regulatory press release 2020-12-29

Xspray Pharma’s HyNap-Nilo receives FDA Orphan Drug Designation for the treatment of Chronic Myeloid Leukemia

Regulatory press release 2020-12-11

Xspray Pharma has decided to await the result of two ongoing clinical studies before submitting its ANDA application

Regulatory press release 2020-11-20

Xspray Pharma publishes Interim Report Q3, January – September 2020

Regulatory press release 2020-10-30

Number of shares and votes in Xspray

Regulatory press release 2020-10-20

Xspray Pharma Has Carried Out a Directed Share Issue Raising Gross Proceeds of Approximately SEK 265 million

Show more

Subscribe

  • Submit to our press releases and get an email every time we publish a press release or report on our website.
  • When clicked on Send I agree that my personal information will be saved. Read more
  • This field is for validation purposes and should be left unchanged.

IR contact

Kerstin Hasselgren, Chief Financial Officer

+46 (0)70 311 16 83

info@xspray.com

Xspray-logo-white

Xspray Pharma AB Råsundavägen 12 169 67 Solna

+46 (0)8 730 37 00 info@xspraypharma.com